ASH 2023 | CAR-T expansion is associated with treatment response, CRS, and cytopenia in patients with R/R MM
Maximilian Merz
• 10 Dec 2023
Maximilian Merz, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, discusses a study utilizing flow cytometry to analyze responses to CAR T-cell therapies in patients with relapsed/refractory (R/R) multiple myeloma (MM). The findings indicate a correlation between CAR-T expansion and treatment response, though this association is accompanied by the increased occurrence of cytokine release syndrome (CRS) and prolonged cytopenia. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria: Amgen, Takeda, BMS, Janssen, Stemline, Roche
